SCHEMBL10244085

SCHEMBL10244085

CCNCCN1CCN(C(=O)OCc2ccccc2)CC1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 3/20 0.56
CA2 P00918 3/20 0.56
CA7 P43166 3/20 0.56
ACKR3 P25106 1/20 0.54
MEN1 O00255 1/20 0.53
KMT2A Q03164 1/20 0.53
NPSR1 Q6W5P4 1/20 0.53
CA9 Q16790 2/20 0.53
SMN1; SMN2 Q16637 3/20 0.52
NPC1 O15118 2/20 0.52
RAB9A P51151 2/20 0.52
SIGMAR1 Q99720 3/20 0.52
TMEM97 Q5BJF2 2/20 0.52
ALDH1A1 P00352 1/20 0.52
PRMT6 Q96LA8 1/20 0.51
TSHR P16473 1/20 0.50
CYP2C19 P33261 1/20 0.50
TNKS O95271 1/20 0.48
PARP1 P09874 1/20 0.48
TNKS2 Q9H2K2 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6642926 0.87 CA1 (0.58) CA1CA2CA7ACKR3MEN1
SCHEMBL6644070 0.85 CA1 (0.56) CA1CA2CA7ACKR3MEN1
SCHEMBL4904424 0.83 SIGMAR1 (0.57) CA1CA2CA7MEN1KMT2A
SCHEMBL10243152 0.83 MEN1 (0.62) CA1CA2CA7MEN1KMT2A
SCHEMBL26025031 0.82 CA1 (0.61) CA1CA2CA7ACKR3MEN1
SCHEMBL27629467 0.82 SIGMAR1 (0.56) CA1CA2CA7MEN1KMT2A
SCHEMBL26642859 0.82 CA1 (0.56) CA1CA2CA7ACKR3MEN1
SCHEMBL92564 0.81 MEN1 (0.61) CA1CA2CA7MEN1KMT2A
SCHEMBL7658562 0.81 L3MBTL1 (0.68) MEN1KMT2ANPSR1SMN1; SMN2NPC1
SCHEMBL3970912 0.81 MEN1 (0.76) MEN1KMT2ANPSR1SMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 CA1 3677/4885CA2 3065/4885CA7 510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.